Updates in the Treatment of Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

home / news-network / updates-in-the-treatment-of-adults-with-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia

Jae Park, MD, reviews the current treatment landscape and emerging options for treating adults with relapsed/refractory B-cell acute lymphoblastic leukemia

A Review of Available Treatment Options for Adult Patients with R/R B-ALL

EP. 1: A Review of Available Treatment Options for Adult Patients with R/R B-ALL

June 28th 2022

Jae Park, MD, shares an overview of available therapeutic options for patients with R/R B-ALL.

Highlights from the Two-Year Follow-Up Results of the ZUMA-3 Trial

EP. 2: Highlights from the Two-Year Follow-Up Results of the ZUMA-3 Trial

June 28th 2022

An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.

Tisagenlecleucel as a Potential Option for Adult Patients with R/R B-ALL

EP. 3: Tisagenlecleucel as a Potential Option for Adult Patients with R/R B-ALL

June 28th 2022

Dr. Jae Park comments on the findings from the ELIANA study and tisagenlecleucel as a potential option for adults with R/R B-ALL.

Considerations and Next Steps For Patients Who Progress on CAR T-Cell Therapy

EP. 4: Considerations and Next Steps For Patients Who Progress on CAR T-Cell Therapy

June 28th 2022

Practical considerations for treatment selection in patients who progress on CAR T-Cell therapy.

Emerging Therapies for Adults with R/R B-ALL

EP. 5: Emerging Therapies for Adults with R/R B-ALL

June 28th 2022